Minneapolis-based specialty pharmacy company ExceleraRx Corp. has been acquired by Stoughton, Mass.-based Shields Health Solutions, the companies announced Tuesday.

Minneapolis-based specialty pharmacy company ExceleraRx Corp. has been acquired by Stoughton, Mass.-based Shields Health Solutions, the companies announced Tuesday.

Shields Health Solutions is acquiring ExceleraRx, the companies announced today. The combined entity will be a specialty pharmacy powerhouse that will serve more 60 health systems and academic medical centers and 700 hospitals that “account for the opportunity of $30 billion in specialty pharmacy revenue,” says the press release about the acquisition.

The specialty pharmacist has a unique role in medication safety. Not only are they responsible for ensuring safe, effective, appropriate use of specialty medications—and ensuring that the patient is educated on their therapy and can be adherent—but they also play a strong role in promoting a positive safety culture within their pharmacy setting.

Specialty Pharmacy Times, a bi-monthly journal and daily news website serving the business and practice of specialty pharmaceuticals and therapy, has expanded its Strategic Alliance Partnership program with the addition of the Excelera Specialty Pharmacy Network, a unique national network of academic institutions and large integrated delivery systems-based specialty pharmacies providing coordinated care to drive higher quality outcomes with complex patients.

Specialty Pharmacy Times, a bi-monthly journal and daily news website serving the business and practice of specialty pharmaceuticals and therapy, has expanded its Strategic Alliance Partnership program with the addition of the Excelera Specialty Pharmacy Network, a unique national network of academic institutions and large integrated delivery systems-based specialty pharmacies providing coordinated care to drive higher quality outcomes with complex patients.

By Jami Schell, PharmD, CSP; Lana Gerzenshtein, PharmD, BCPS, CSP; and Tim Paine Defined as “the conditions in which people…

ACHC announces the renewal of its partnership with ExceleraRx Corp. | Pharmacies in the Excelera® Network will receive special pricing on…

As the COVID-19 pandemic spread across the country and hospitals reduced in-person visits to a bare minimum, health systems—such as…

By Martha Stutsky, PharmD, BCPS; and Osama Abdelghany, PharmD, MHA, BCOP Smilow Cancer Hospital at Yale New Haven Health System…

By Claudia S. Castro, PharmD, MS, BCOP, BCGP; and Amanda Manoogian, PharmD, BCOP The prevalence of individuals living with cancer…

Dueling misperceptions among health plans and payors about the value each brings to patient care can make it difficult for…

By Vinay Sawant, RPh, MPH, MBA; Ayse Hursid, PharmD; Osama Abdelghany, PharmD, MHA, BCOP; and Terri Sue Bukowski, PharmD, CSP…

Erin Kelley, PharmD, BCOP, and Jeff Engle, PharmD, MS, Fairview Health

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is the most common type of leukemia in adults and accounts for approximately 37% of new leukemia cases. An estimated 20,720 new cases of and 3930 deaths from CLL will occur in the United States in 2019.

By Don Amorosi, Chief Operating Officer; and Becky Rand, MHRM, Vice President of Manufacturer Relations ExceleraRx Corp

Although the prevalence of health system-based specialty pharmacies has grown steadily over the past decade, 2020 will mark a critical year. Payers, providers, and health systems themselves are increasingly recognizing the important role integrated delivery solutions play in value-based care initiatives.